Drug Shortage Report for LORAZEPAM INJECTION USP
Report ID | 127901 |
Drug Identification Number | 02388669 |
Brand name | LORAZEPAM INJECTION USP |
Common or Proper name | Lorazepam Injection USP |
Company Name | PFIZER CANADA ULC |
Market Status | MARKETED |
Active Ingredient(s) | LORAZEPAM |
Strength(s) | 4MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
Packaging size | 10 x 1mL vial |
ATC code | N05BA |
ATC description | ANXIOLYTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-12-18 |
Estimated end date | 2021-03-31 |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2020-12-21 |
Company comments | Inventory is on preventative allocation. |
Health Canada comments | |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.